We have located links that may give you full text access.
The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast cancer.
Clinical Nuclear Medicine 2023 January 17
PURPOSE: Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC.
METHODS: This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time.
RESULTS: Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations.
CONCLUSIONS: This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.
METHODS: This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time.
RESULTS: Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations.
CONCLUSIONS: This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app